Novo Nordisk begins late-stage trial to test lower-dose oral Wegovy for weight loss

The 60-week, randomised Phase III study will enrol 450 adults with a BMI of 30 or above, or 27 or above with at least one obesity-related health condition

AstraZeneca’s Enhertu delivers first-line win in HER2-mutant lung cancer trial

The trial will continue to assess secondary endpoints, including overall survival

AstraZeneca halts Phase III lung cancer trial after drug unlikely to meet key endpoints

The decision follows a planned review by the Independent Data Monitoring Committee

PhenoNet gets FDA green light for Phase 3 Alzheimer’s trial

The trial will evaluate PHENOGENE-1A in both APOE4 carriers and non-carriers

Indraprastha Apollo launches clinical trial for non-invasive tremor treatment

Delhi hospital begins evaluating ZAP-X Gyroscopic Radiosurgery System for severe essential tremor, offering a frame-free alternative for patients unresponsive to medication

Obsidian advances melanoma cell therapy toward potential FDA filing

With first patient in registration-ready trial

BostonSight and LVPEI launch clinical trial to assess mental health impact of PROSE and SCLERAL lenses

BostonSight PROSE and BostonSight SCLERAL are FDA-cleared medical devices used as part of customized medical treatment

Allergan Aesthetics’ BOTOX Cosmetic moves closer to new jawline treatment approval

This submission builds on the depth and versatility of BOTOX Cosmetic and reflects our continued investment in advancing aesthetic medicine

Moleculin reports promising preliminary phase II/III data for leukaemia drug Annamycin

Blinded interim analysis shows 37% composite remission rate for drug that aims to treat relapsed or refractory acute myeloid leukaemia

Novo Nordisk's Phase 3 ZEUS trial misses cardiovascular endpoint for Ziltivekimab

The study reported a hazard ratio of 0.99 versus placebo

Pfizer’s LITFULO clears two Phase 3 vitiligo trials paving way for global regulatory filings

The trials represent the largest Phase 3 clinical program to date evaluating an oral systemic therapy for the disease

Parexel recognised among world's top disability inclusive businesses

Recognition highlights company's commitment to accessible workplaces and inclusive clinical research

Bio-Thera begins human trial of next-generation cancer drug in advanced solid tumors

AstraZeneca’s Sone-Ve delivers survival breakthrough in advanced gastric cancer trial

The findings could significantly expand the number of patients eligible for targeted therapy

Merck unveils early global access plan for monthly HIV prevention pill ahead of phase 3 completion

Merck said its strategy combines early generic licensing, regional manufacturing partnerships in Africa and Latin America

Phase 3 trial of Zydus' Desidustat begins with hope for sickle cell patients

203-day study with ICMR to evaluate the efficacy and safety of the oral therapy in 164 patients with sickle cell disease

Takeda’s zasocitinib delivers broad skin clearance in Phase 3 psoriasis trials

The treatment also produced statistically significant improvements in nail psoriasis severity compared with placebo

Grifols advances immunoglobulin pipeline with two new Phase 3 trials

The SIGMA trial will assess GAMUNEX-C, an intravenous immunoglobulin

Oxford launches world's first human trial of Bundibugyo ebola vaccine

The BD-Ebov trial, led by Oxford Vaccine Group, will evaluate the safety and immune response of the ChAdOx1 BDBV vaccine in 50 healthy volunteers aged 18 to 55

Moderna doses first US patient in Phase 1 trial of shared-antigen mRNA cancer therapy

The experimental therapy is designed to target seven tumor antigens commonly shared across multiple cancer types